Pancreatic fibrosis is the hallmark of chronic pancreatitis, currently an incurable disease. Pancreatitis fibrosis is caused by deposition of extracellular matrix (ECM) and the underlying pathological mechanism remains unclear. In addition to its broad biological activities, TGF-β is a potent pro-fibrotic factor and many in vitro studies using cell systems have implicated a functional role of TGF- in the pathogenesis of pancreatic fibrosis. We analyzed the in vivo role of TGF- pathway in pancreatic fibrosis in this study. Smad7, an intracellular inhibitory protein that antagonizes TGF- signaling, was specifically expressed in the pancreas using a transgenic mouse model. Chronic pancreatitis was induced in the mouse with repeated administration of cerulein.
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Introduction
Transforming growth factor beta (TGF-β) is a multipotent cytokine that plays important roles in the regulation of cell growth, cell differentiation, apoptosis, immune response, and cancinogenesis [1, 2] . In addition, TGF-β has been shown to be a potent pro-fibrotic factor that is implicated in the pathogenesis of fibrosis in the liver, pancreas, lung, and other organs [3] [4] [5] .
TGF-β ligand initiates its downstream signaling by binding to type I and type II receptors, followed by activation of downstream Smad proteins. Three classes of Smad proteins are involved in the signal transduction and regulation of TGF-β family receptors: receptor-regulated Smad (R-Smad), Co-mediator Smad (Co-Smad or Smad4), and inhibitory Smad (I-Smad) [6] . R-Smads are phosphorylated by the serine/theronine kinase domain of type I receptor. Activated R-Smad and Smad4 form a protein complex that is translocated into the nucleus and regulates the transcription of target genes. Smad7 belongs to the I-Smad subfamily which negatively regulates TGF-β signaling by competing with R-Smads for receptor binding [7] .
The mechanism of chronic pancreatitis is obscure and the disease cannot be cured at present.
Chronic pancreatitis is characterized by the gradual loss of exocrine and endocrine cells with the development of fibrosis. The degradative process is thought to be caused by the injury of epithelium and the resulting recruitment of inflammatory cells [8] . Along with the disappearance of exocrine compartment, mainly acinar cells, the increasingly formed extracellular matrix (ECM) takes over the place, leading to fibrosis [9] .
The mechanism of fibrosis is poorly understood. Recent evidence suggests that TGF-β promotes pancreatic fibrogenesis. TGF-β activates pancreas stellate cells (PSCs), which are
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ACCEPTED MANUSCRIPT 5 thought to be the culprit of fibrosis [10, 11] , in both autocrine and paracrine manners [9, 12] . The activated PSCs secret ECM such as type I collagen, fibronectin, laminin, and MMPs [13] [14] [15] . It has been shown that α-smooth muscle actin (α-SMA) is a marker of PSCs. Transgenic mice overexpressing TGF-β in islet cells developed exocrine pancreas fibrosis [16] . Consistently, TGF-β expression was observed in acinar cells adjacent to fibrotic areas in human chronic pancreatitis tissues [10] .
Recent studies have revealed that inhibition of TGF-β signaling results in improvement of fibrosis. Inhibition of TGF-β by a neutralizing antibody reduced ECM production in cerulein-induced pancreatitis in rats [17] . Overexpression of a dominant-negative mutant form of TGF-β type II receptor also reduced pancreatic fibrosis [18, 19] . Taken together, these studies have revealed that TGF-β contributes to fibrogenesis in pancreas and inhibition of TGF-β signaling has a beneficial role to improve pancreatic fibrogenesis. However, whether or not Smad7 is implicated in pancreatic fibrogenesis has not been investigated. We hypothesize that Smad7 could decrease pancreatic fibrosis by interrupting TGF-β signaling. We analyzed this hypothesis using a transgenic mouse with pancreas-specific expression of Smad7. As described in this study, we found that overexpression of Smad7 is able to ameliorate pancreatic fibrosis induced by chronic administration of cerulein.
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Materials and Method

Animals
The Smad7 transgenic mice were generated as previously described [20] . All transgenic mice were maintained be crossing with C57BL/6J strain mice.
Identification of transgenic mice
Genomic DNA was extracted from a 2-mm tail biopsy: The tissues were incubated with 50mmol/L NaOH at 100 o C for 1 hour, neutralized with 1M Tris-HCl(pH 8.0). The samples were centrifuged and the supernatant was used in PCR genotyping with primers 5'-CTTTGTACTTTCATGTCACCTGTGC-3' and 5'-CGCCGGACGAGCGCAGATCGTT-3'.
Tissue harvest, protein extraction, and Western blotting analysis
Pancreas and other tissues were removed and washed with cold PBS, homogenized, and solubilized in cold RIPA buffer (50mM Tris-HCl at pH7.4, 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl, and 1 mM EDTA) containing protease inhibitor cocktail (Sigma-Aldrich, Saint Louis, MO, USA). Proteins from various tissues were resolved by SDS/PAGE, and transferred to PVDF membranes (Millipore, Billerica, MA, USA). The
Myc-tagged Smad7 were detected by Western blotting using a mouse anti-Myc antibody (Santa Cruz, Santa Cruz, CA, USA).
Mouse experimental protocol
Female and male mice of 2-month-old were treated with cerulein to induce chronic pancreatitis as previously described [21] . Briefly, 50 μg/kg cerulein (BACHEM California Inc., Torrance, CA, USA) was injected intraperitoneally every hour for 5 consecutive times. Such injection was repeated for 3 days per week up to a total of 8 weeks. Saline was injected as control.
Mice were sacrificed four days after the final cerulein treatment. The pancreas was swiftly removed and fixed in Bouin's solution (75% picric acid saturated aqueous solution, 25% of 40% formaldehyde, and 5% glacial acetic acid).
Histological analysis
Mouse pancreas specimens were fixed in Bouin's solution overnight at room temperature and embedded in paraffin using standard techniques. The paraffin-embedded sections (5 μm) were stained with hematoxylin/eosin (H&E) to determine the histopathological features.
Immunohistochemistry and quantitative analysis
The immunohistochemistry was done on 5 μm sections using SABC (mouse/rabbit IgG) kit 
Results and Discussion
In order to determine whether or not Smad7 plays a role in pancreatic fibrosis, we generated a transgenic mouse model with pancreatic expression of Smad7 using the strategy as previously described by us [20] . The plasmid used for the transgenic mouse contains a -205/+8-bp rat elastase I gene promoter/enhancer, a Smad7 cDNA with a Myc-tag at its N terminus, and an SV40 poly(A) tail [20] . The plasmid was linearized and microinjected into the zygote with C57BJ/6L
(female) and CBA (male) background. From 155 offspring, we found that 24 mice carried the Smad7 transgene and only two of them expressed the exogenous Smad7 gene. These two founders were crossed with mice of C57BJ/6L background to generate Smad7 transgenic mice for the study.
The transgenic mice were identified by genomic PCR (Fig. 1A) to determine the presence of the Smad7 transgene, and Western blotting to determine the expression of exogenous Smad7 with a Myc tag (Fig. 1B) . Consistent with previous report [20] , the exogenous Smad7 was specifically expressed in the pancreas, but not in other tissues (Fig. 1C ).
We induced chronic pancreatitis by repeated induction of acute pancreatitis as previously reported [19, 21] . Considering that premalignant ductal lesions occurs the Smad7 transgenic mice 6 months [20] , we chose 2-month-old mice for induction of chronic pancreatitis. Injection of cerulein for 4 weeks provoked loss of acinar cells and ECM deposition in wild type mice (Fig. 2) .
Pancreatic fibrosis occurred after another 4 weeks' injection with the hallmarks of chronic pancreatitis (Fig. 2C) , accompanied by hemorrhage and inflammatory cell infiltration (Fig. 2D ).
We also observed acinar-to-ductal metaplasia ( Fig. 2E and F) , another important pathological change in which acinar cells lose their characteristic zymogen granules and acquire the features of
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We next determined whether exogenous expression Smad7 is able to affect chronic pancreatitis induced by cerulein. We compared the pathological changes of pancreas in 6 wild type mice and 23 Smad7 transgenic mice. The representative results are shown in Fig. 3 . We found that exogenous expression of Smad7 had a protective role in the development of chronic pancreatitis. The loss of acinar cells in Smad7 transgenic mice was much less than the wild type animals. Moreover, some areas in Smad7 transgenic mice were intact without acinar atrophy. As collagen I is the main component of fibrosis, we used immunohistochemistry to determine the expression level of collagen I in these mice. As shown in Fig. 4A , the staining of collagen I was reduced in Smad7 transgenic mice in comparison with the wild type animals, suggesting that the deposition of ECM was markedly reduced by overexpression of Smad7 in the pancreas. In addition, we analyzed the expression level of fibronectin, another major ECM component induced by TGF-. As shown in Fig. 5 , fibronectin was significantly reduced in the pancreas when Smad7 was overexpressed. Therefore, these data provided additional evidence that Smad7 is able to inhibit ECM deposition in the pancreas.
We also analyzed PSCs in these mice, as PSC is the source of pancreatic fibrosis and TGF-β can cause ECM secretion by activating PSCs [11, 12] . We examined the expression of α-smooth muscle actin (α-SMA), a marker of activated PSC in the pancreas after cerulein injections. Our data reveals that activated PSCs were greatly reduced in the Smad7 transgenic mice (Fig. 6 ). Thus the exogenous Smad7 appears to inhibit PSC activation through inhibition of TGF-β signaling and
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The molecular mechanism of chronic pancreatitis is not well understood. Partly because of this, there is currently no cure to pancreatitis except for pancreatectomy with limited success.
Recent studies have indicated that TGF-β signaling is closely implicated in the development of fibrosis in chronic pancreatitis. Tissue trauma in chronic pancreatitis may stir inflammatory response which in turns summons inflammatory cells into the pancreas. The inflammatory cells secret inflammatory mediators including TGF-β, which activates PSCs to secrete ECM. If the inflammation in the pancreas persists, the increased ECM deposition would occupy the enlarged interlobular space, accompanied by atrophy and loss of acinar cells. Several groups have found that inhibition of TGF-β signaling leads to decrease of activated PSCs and pancreatic fibrosis [17] [18] [19] . As the major function of TGF- is to activate PSCs [4] , we postulate that the decreased staining of -SMA by Smad7 overexpression (Fig. 6) is mainly due to a decrease of PSC activation, instead of reducing the number of PSCs. In addition, TGF- has been shown to enhance deposition of ECM, a major mechanism underlying the fibrosis-promoting activity of TGF-. We believe that the major effect of Smad7 in reducing pancreatic fibrosis is via inhibiting TGF--induced ECM deposition, rather than accelerating the degradation of deposited ECM.
Interestingly, Lee et al recently showed the RECK, a novel membrane-anchored MMP inhibitor, can be maintained by TGF- [22] , indicating that TGF- signaling may promote ECM accumulation by preserving the protease inhibitory activity of RECK. This is consistent with the finding that Smad7 was able to reverse the RECK-maintaining activity of TGF- [22] .
Nevertheless, our study provide another piece of evidence that inhibition of intracellular TGF-β
ACCEPTED MANUSCRIPT 12 signaling by Smad7 also reduces fibrosis and activation of PSCs in cerulein-induced chronic pancreatitis. Therefore, increasing Smad7 expression in the pancreas could potentially serve as new strategy to treat fibrosis in chronic pancreatitis. 
Figure Legends
